ITMCTR1900002589
Not yet recruiting
Phase 1
A Randomized Double-blind Clinical Study for the Effect of Qingzhi Huayu Prescription on SDLDL-C/LDL-C in Patients With Coronary Heart Disease
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine0 sitesTBD
ConditionsCoronary Atherosclerotic Heart Disease
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Coronary Atherosclerotic Heart Disease
- Sponsor
- Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Objectives: patients have coronary atherosclerotic heart disease (CAD) with high sdLDL\-C.
- •Selection criteria:
- •1\) Age between 18 and 80 (including 18 and 80\);
- •2\) Gender is not limited;
- •3\) Coronary angiography showed that the stenosis of any coronary artery exceeded 50%.
- •4\) sdLDL\-C (\>\= 52\.6mg/dL)
- •5\) Patients willing to receive atorvastatin treatment and Traditional Chinese Medicine treatment.
Exclusion Criteria
- •1\) History of statin\-related liver lesions and/or myopathy;
- •2\) Patients with malignant tumors (excluding those cured);
- •3\) Patients with serious diseases of heart, lung, kidney, brain and blood;
- •4\) Patients with severe neurological and psychiatric disorders (such as epilepsy, depression, mania, seizures, schizophrenia, etc.);
- •5\) Pregnant women and lactating women or those who have pregnancy plans and are unwilling to contracept during the study period;
- •6\) Participate in other clinical researchers at the same time;
- •7\) Researchers think that it is not suitable for patients to participate in this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Study to compare the Efficacy and Safety of BCD-264 in the treatment of Relapsed and Refractory Multiple MyelomaHealth Condition 1: C900- Multiple myelomaCTRI/2024/03/063867JSC BIOCAD, Russia
Active, not recruiting
Phase 1
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancerProgressive Metastatic Medullary Thyroid CancerMedDRA version: 21.1 Level: PT Classification code 10027105 Term: Medullary thyroid cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-003402-40-HUExelixis, Inc.250
Active, not recruiting
Phase 1
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancerProgressive Metastatic Medullary Thyroid CancerMedDRA version: 21.1Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-003402-40-PLExelixis, Inc.250
Active, not recruiting
Phase 1
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancerEUCTR2013-003402-40-FRExelixis, Inc.188
Active, not recruiting
Phase 1
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancerProgressive Metastatic Medullary Thyroid CancerMedDRA version: 21.1Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-003402-40-SEExelixis, Inc.250